Search | IOVS | ARVO Journals

View

Showing 1 – 11 of 11

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Ocular and systemic complement activation during anti-VEGF treatment and AREDS 2 dietary supplementation in neovascular age-related macular degeneration

Philip Enders; Lebriz Altay; Caroline Gietzelt; Julia Lemke; Vasilena Sitnilska; Friederike Schaub; Claus Cursiefen; Sascha Fauser

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3685. doi:

Retina August 2019

Elevated Steroid Hormone Levels in Active Chronic Central Serous Chorioretinopathy

PDF

Rosa L. Schellevis; Lebriz Altay; Asha Kalisingh; Timo W. F. Mulders; Vasilena Sitnilska; Carel B. Hoyng; Camiel J. F. Boon; Joannes M. M. Groenewoud; Eiko K. de Jong; Anneke I. den Hollander
TAGS: central serous chorioretinopathy, steroid hormone, steroids, hormones
Invest. Ophthalmol. Vis. Sci.. 2019; 60(10):3407-3413. doi: https://doi.org/10.1167/iovs.19-26781

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Risk factors for Fellow Eye Progression in Patients with Unilateral Exudative Age-Related Macular Degeneration

Julia Lemke; Vasilena Sitnilska; Caroline Gietzelt; Tina Schick; Carel C B Hoyng; Anneke I Den Hollander; Sascha Fauser; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1134. doi:

ARVO Annual Meeting Abstract July 2019

Non-genetic risk factors for age-related macular degeneration in nonagenarians

Vasilena Sitnilska; Tina Schick; Anneke I Den Hollander; Carel C B Hoyng; Sascha Fauser; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1135. doi:

ARVO Annual Meeting Abstract July 2019

Predictive Value of Pachyvessels in Patients with Central Serous Chorioretinopathy (CSCR) Treated by Photodynamic Therapy (PDT)

Johanna Wiedemann; Vasilena Sitnilska; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5011. doi:

ARVO Annual Meeting Abstract July 2018

Salivary alpha amylase activity is increased in active central serous chorioretinopathy

Lebriz Altay; Paula Scholz; Vasilena Sitnilska; Elon H. Van Dijk; Alberto M. Pereira; Femke M. van Haalen; Isha Akhtar; Camiel Boon; Sascha Fauser

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3128. doi:

ARVO Annual Meeting Abstract July 2018

Phenotypic risk factors for treatment outcome in patients with chronic central serous chorioretinopathy

Vasilena Sitnilska; Robert Hoerster; Sascha Fauser; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3131. doi:

ARVO Annual Meeting Abstract July 2018

Dynamics of hyperreflective foci shortly after anti-VEGF treatment in neovascular age-related macular degeneration

Manuel Hermann; Vasilena Sitnilska; Philip Enders; Sascha Fauser; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3232. doi:

ARVO Annual Meeting Abstract July 2018

Progression to late AMD: Role of SDOCT-biomarkers in patients with drusenoid PED

Julia Lemke; Vasilena Sitnilska; Eveline Kersten; Tina Schick; Philip Enders; Carel C B Hoyng; Anneke I Den Hollander; Sascha Fauser; Lebriz Altay

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2377. doi:

ARVO Annual Meeting Abstract June 2017

Genetic, environmental and phenotypic risk factors for progression of age-related macular degeneration

Vasilena Sitnilska; Eveline Kersten; Lebriz Altay; Tina Schick; Philip Enders; Carel C B Hoyng; Anneke I Den Hollander; Sascha Fauser

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):176. doi:

ARVO Annual Meeting Abstract June 2017

Early changes in retinal morphology during the first three weeks after anti-VEGF (re-)treatment for neovascular age-related macular degeneration

Philip Enders; Vasilena Sitnilska; Lebriz Altay; Sascha Fauser

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):22. doi:

Advertisement